Altretamine
Alkylating Agent
DB00488
Approved Indication
For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
0
Targets
0
Resistance Mutations
4
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The precise mechanism by which altretamine exerts its cytotoxic effect is unknown although it is classified as an alkylating anti-neoplastic agent. Through this mechanism, the drug is metabolized into alkylating agents by N-demethylation. These alkylating species consequently damage tumor cells.
Details
DrugBank ID
DB00488 ↗
Approval Date
1990-12-26
Molecular Weight
210.2794 g/mol
Drug Class
Alkylating Agent
ATC Codes
L01XX03
Synonyms
Altretamin, Altretamina, Altrétamine
PubChem
CID: 2123 ↗
ChEMBL
CHEMBL1455 ↗
SMILES
CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
ADMET Profile
Computing properties…
Drug References (DrugBank)